Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-tumor Activity

NCT05109975 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.

NCT NCT05109975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05109975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-tumor Activity
Lead sponsor
Debiopharm International SA
Phase
Phase 1
Overall status
Terminated
Start date
November 5, 2021
Completion date
April 24, 2026
Enrollment
93 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors